

Date: December 05, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Media Release – “Senores Pharmaceuticals receives Philippine FDA approval for 10 products”

Kindly find enclosed herewith a copy of Media Release being issued by the Company on the captioned subject.

The same is also being uploaded on the website of the Company at www.senorespharma.com.

This is for information and records.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As mentioned above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Senores Pharmaceuticals receives Philippine FDA approval for 10 products

Ahmedabad, Gujarat, 05th December 2025 – Senores Pharmaceuticals Limited today announced that it has received marketing authorizations from the Philippine Food and Drug Administration (FDA) for a basket of 10 products across Therapies like Cardiovascular, CNS, and Pain management, etc. This milestone marks a significant step in the company's strategy to expand its footprint in Southeast Asia and enhance access to affordable healthcare.

The approvals provide Senores Pharmaceuticals with a strong platform to serve the Philippines. The market size of these particular drugs in the Philippines is valued at US \$23 million, underscoring the immense opportunity for growth and patient impact.

"These approvals reaffirm our commitment to delivering high-quality, affordable treatments for patients," said Swapnil Shah, Managing Director of Senores Pharmaceuticals. "Philippines is a critical market in our regional expansion strategy, and this achievement strengthens our position as a trusted partner in advancing healthcare."

With these regulatory endorsements, strong manufacturing capabilities, Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region, leveraging its expertise, global partnerships, and uncompromising quality standards to improve treatment outcomes and broaden patient access.

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited ('Senores') is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 32 own ANDA and 32 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 390 product registrations and 820+ product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US, which is USFDA approved and DEA/BAA compliant, and the other is in Chhatral, Ahmedabad, India, approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

MEDIA RELEASE**Safe Harbour Statement:**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact

**Company : SENORES PHARMACEUTICALS LIMITED**

CIN: L24290GJ2017PLC100263

Mr. Deval Shah

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

SGA Strategic Growth Advisors

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899